Mindray Doubles Patient Monitor Biz, Builds U.S. Presence With Acquisition
This article was originally published in The Gray Sheet
Executive Summary
China-based Mindray Medical will supply components for Datascope's patient monitoring business unit after acquiring the subsidiary for $202 million in a deal announced March 11
You may also be interested in...
China’s Mindray Refutes Merit Of Report That Sent Stock Plummeting
Mindray stock recovers from freefall after allegations that China’s leading medical device company overstated its earnings and engaged in fraudulent accounting practices.
People In Brief
Roche changing of guard: Roche Molecular Diagnostics CEO Daniel O'Day will head the Swiss firm's entire test business at year-end when current diagnostics CEO Juergen Schwiezer retires, Roche said Sept. 8. O'Day's new title will be chief operating officer, rather than CEO, of the Diagnostics Division, but like Schwiezer he will report directly to Roche CEO Severin Schwan. Under the new structure, the head of the diabetes care division, Burkhard Piper, will report to O'Day, rather than to Schwan, as Piper has been doing since 2008 when Schwan took over the company. Schwiezer took the helm of the diagnostics unit last year to replace Schwan, who previously ran the laboratory products business (1"The Gray Sheet" Oct. 8, 2007). Also as part of the changes, Pharma Division head William M. Burns will be replaced by Pascal Soriot, who has led Genentech since Roche acquired the biotech firm earlier this year
People In Brief
Roche changing of guard: Roche Molecular Diagnostics CEO Daniel O'Day will head the Swiss firm's entire test business at year-end when current diagnostics CEO Juergen Schwiezer retires, Roche said Sept. 8. O'Day's new title will be chief operating officer, rather than CEO, of the Diagnostics Division, but like Schwiezer he will report directly to Roche CEO Severin Schwan. Under the new structure, the head of the diabetes care division, Burkhard Piper, will report to O'Day, rather than to Schwan, as Piper has been doing since 2008 when Schwan took over the company. Schwiezer took the helm of the diagnostics unit last year to replace Schwan, who previously ran the laboratory products business (1"The Gray Sheet" Oct. 8, 2007). Also as part of the changes, Pharma Division head William M. Burns will be replaced by Pascal Soriot, who has led Genentech since Roche acquired the biotech firm earlier this year